Atacicept
As of the edition of 20 October 2026, Atacicept is a protein: marketed, first approved in 2026 (US); acts on TNFSF13 and TNFSF13B; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Trutakna
- First approved
- 7 July 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Vera Therapeutics
- Registered trials
- 18, 9 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles; Eye
US protection
US protection ends in 2038.
US protection ends in 2038, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Vera Therapeutics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Atacicept.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 13 | 4 | 3 | 6 |
| Phase 3 | 4 | 1 | 1 | 2 |
| All trials | 18 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Vera Therapeutics | Originator and Lead sponsor of trials | 2022 to now |